4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Sponsor
Shenzhen Geno-Immune Medical Institute
Study ID
NCT04637503
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • GD2, PSMA and CD276 CAR-T cells — BIOLOGICAL
    infusion, for 1x10\^6\~1x10\^7 cells/kg via IV

Study Details

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.

Key Dates

First listed
Nov 19, 2020
Start date
Dec 31, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: effectiveness of CAR-T cells targeting GD2, PSMA and CD276
    Gene-modified T cells are designed to kill tumor cells through specific recognition of GD2, PSMA and CD276. This study will evaluate the side effects and effective doses of GD2, PSMA and CD276 CAR-T cells in treating refractory and recurrent NB

Primary Outcome Measure

Number of patients with adverse events [ Time Frame: 3 year ]

Central Contacts

Find similar trials

Nationwide
Neuroblastoma trialsOncology trialsPediatric oncology trials

Related Studies